Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Market: Market:

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Genprex to Participate in Upcoming March Investor Conferences BusinessWire - Mon Mar 1, 7:30AM CST
CMTX - Mon Mar 1, 7:30AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will...

GNPX : 5.38 (+4.26%)
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants BusinessWire - Tue Feb 9, 7:30AM CST
CMTX - Tue Feb 9, 7:30AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced it has entered...

GNPX : 5.38 (+4.26%)
Genprex Announces Formation of Clinical Advisory Board BusinessWire - Mon Feb 8, 2:30PM CST
CMTX - Mon Feb 8, 2:30PM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the...

GNPX : 5.38 (+4.26%)
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing PR Newswire - PRF - Mon Feb 8, 7:35AM CST
CMTX - Mon Feb 8, 7:35AM CST

, /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the Small and Microcap Showcase are now available for...

BIGG.CN : 1.300 (+10.17%)
NTAR.CN : 5.300 (+4.13%)
MIRI.LN : 52.000 (unch)
BBKCF : 1.0264 (+11.57%)
EXPFF : 0.3325 (+15.13%)
MMDDF : 0.6970 (+2.50%)
NEXCF : 4.1724 (+4.31%)
ALVOF : 0.6500 (-7.14%)
ETIHY : 3.6000 (+18.42%)
LLEIF : 7.9300 (unch)
GNPX : 5.38 (+4.26%)
BSGM : 4.50 (+1.12%)
VNRX : 4.18 (+2.45%)
CTXR : 2.08 (+2.46%)
VERB : 2.28 (unch)
LGIQ : 7.3900 (-1.47%)
CETY : 0.0851 (-1.05%)
SLBG : 2.9000 (-9.38%)
SKYE : 0.0862 (-21.28%)
Genprex Recognizes World Cancer Day BusinessWire - Thu Feb 4, 7:30AM CST
CMTX - Thu Feb 4, 7:30AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today that...

GNPX : 5.38 (+4.26%)
Genprex Issues Shareholder Letter and Provides Corporate Update BusinessWire - Mon Feb 1, 12:30PM CST
CMTX - Mon Feb 1, 12:30PM CST

--Company looks toward launching key clinical trials in lung cancer in 2021

GNPX : 5.38 (+4.26%)
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th PR Newswire - PRF - Thu Jan 28, 7:35AM CST
CMTX - Thu Jan 28, 7:35AM CST

, /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small and Microcap Showcase.  Individual investors, institutional...

VNRX : 4.18 (+2.45%)
BIGG.CN : 1.300 (+10.17%)
MIRI.LN : 52.000 (unch)
BSGM : 4.50 (+1.12%)
GNPX : 5.38 (+4.26%)
VERB : 2.28 (unch)
CTXR : 2.08 (+2.46%)
EMBI : 0.0900 (+1.69%)
SKYE : 0.0862 (-21.28%)
BBKCF : 1.0264 (+11.57%)
CETY : 0.0851 (-1.05%)
EXPFF : 0.3325 (+15.13%)
MMDDF : 0.6970 (+2.50%)
SLBG : 2.9000 (-9.38%)
ALVOF : 0.6500 (-7.14%)
ETIHY : 3.6000 (+18.42%)
LGIQ : 7.3900 (-1.47%)
LLEIF : 7.9300 (unch)
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4 BusinessWire - Wed Jan 27, 7:30AM CST
CMTX - Wed Jan 27, 7:30AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.38 (+4.26%)
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo BusinessWire - Thu Jan 21, 7:30AM CST
CMTX - Thu Jan 21, 7:30AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.38 (+4.26%)
Genprex to Present at NobleCon17 on January 19 BusinessWire - Thu Jan 14, 4:30AM CST
CMTX - Thu Jan 14, 4:30AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.38 (+4.26%)
Genprex Achieves Major Manufacturing Milestone for REQORSA(TM) Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer BusinessWire - Wed Jan 13, 5:00AM CST
CMTX - Wed Jan 13, 5:00AM CST

Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that...

GNPX : 5.38 (+4.26%)
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants BusinessWire - Thu Dec 24, 9:02AM CST
CMTX - Thu Dec 24, 9:02AM CST

Genprex, Inc. (Nasdaq: GNPX) ("Genprex" or the "Company"), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the...

GNPX : 5.38 (+4.26%)
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants BusinessWire - Tue Dec 22, 9:15AM CST
CMTX - Tue Dec 22, 9:15AM CST

Genprex, Inc. (Nasdaq: GNPX) ("Genprex" or the "Company"), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it...

GNPX : 5.38 (+4.26%)
Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA(TM) Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer BusinessWire - Tue Dec 22, 5:32AM CST
CMTX - Tue Dec 22, 5:32AM CST

--Achievement Highlighted by Important Process Improvements and Significantly Improved Economies of Scale

GNPX : 5.38 (+4.26%)
Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session Zacks - Thu Dec 17, 7:47AM CST
Zacks Equity Research - ZACKS - Thu Dec 17, 7:47AM CST

Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

RGEN : 221.73 (+4.40%)
GNPX : 5.38 (+4.26%)
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy BusinessWire - Tue Dec 8, 4:16AM CST
CMTX - Tue Dec 8, 4:16AM CST

--Manufacturing Technology Transfer Marks Major Company Milestone

GNPX : 5.38 (+4.26%)
Genprex to Present at the Benzinga Global Small Cap Conference on December 8 BusinessWire - Thu Dec 3, 4:17AM CST
CMTX - Thu Dec 3, 4:17AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.38 (+4.26%)
Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer BusinessWire - Mon Nov 30, 10:05AM CST
CMTX - Mon Nov 30, 10:05AM CST

--Company expects to recruit approximately 10 sites across the United States

GNPX : 5.38 (+4.26%)
Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 BusinessWire - Tue Nov 24, 4:16AM CST
CMTX - Tue Nov 24, 4:16AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.38 (+4.26%)
Genprex to Participate in Panel at Life Sciences Summit on November 17 BusinessWire - Wed Nov 11, 4:16AM CST
CMTX - Wed Nov 11, 4:16AM CST

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 5.38 (+4.26%)
Please wait...

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Tue Sep 8, 4:25PM CDT
See More
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot